Alexanders (ALX) Stock

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce the results of matters voted on at the Company's Annual General and Special Meeting of shareholders of the Company (the "Shareholders") held this morning at 10:00 AM (Vancouver time) (the "Meeting"). At the Meeting, Shareholders were asked to vote on resolutions approving, among other things, the acquisition by Greenridge Exploration Inc. ("Greenridge") (CSE: GXP) of all of the outstanding and issued common shares of ALX (the "ALX Shares") by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement").

Alexander's, Inc. has underperformed since 2019, with a -1.7% TSR compared to SPY's 113%, due to declining profitability and rich valuations. Despite increasing NOPAT since 2020, the Company's GAAP net income and NOPAT margins have declined from 2019 highs, impacting overall profitability. Management has created value with $154 million in economic earnings since 2019, but ALX remains overvalued with unrealistic growth expectations.

Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.84 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.63 per share a year ago.

PARAMUS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2024 today and reported:

Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers

PARAMUS, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on November 29, 2024 to stockholders of record on November 11, 2024.

PARAMUS, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2024 with the U.S. Securities and Exchange Commission and issue its third quarter earnings release on Monday, November 4, 2024, before the New York Stock Exchange opens.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - October 11, 2024) - Greenridge Exploration Inc. (CSE: GXP) (FSE: HW3)  ("Greenridge" or the "Company") and ALX Resources Corp. ("ALX" and collectively with Greenridge, the "Parties") (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) are pleased to announce the signing of a binding arrangement agreement (the "Arrangement Agreement") dated October 11, 2024 pursuant to which Greenridge will acquire all of the outstanding and issued common shares of ALX (the "Transaction"). The Transaction is an arm's length transaction that will create a leading Canadian uranium exploration company with interests in sixteen (16) uranium exploration projects that total approximately 220,000 hectares across renowned Canadian uranium districts including the Athabasca Basin, Thelon Basin and Elliot Lake.